ArticleJournal of virology2018
Control of Heterologous Simian Immunodeficiency Virus SIV
Open access · hybridAbstract read
In one paragraph
Article in Journal of virology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Safety and efficacy of toll-like receptor agonists as therapeutic agents and vaccine adjuvants for infectious diseases in animals: a systematic review.Frontiers in veterinary science · 2024Pooled it
- Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challenge.PLoS pathogens · 2020Trial
- Enhancing functional antibody responses against HIV envelope V1V2 through vaccine formulations.Frontiers in immunology · 2025Article
- Review
- Viral vector delivered immunogen focuses HIV-1 antibody specificity and increases durability of the circulating antibody recall response.PLoS pathogens · 2023Article
- Direct intranodal tonsil vaccination with modified vaccinia Ankara vaccine protects macaques from highly pathogenic SIVmac251.Nature communications · 2023Article
- Polyfunctional antibodies: a path towards precision vaccines for vulnerable populations.Frontiers in immunology · 2023Review
- Differential V2-directed antibody responses in non-human primates infected with SHIVs or immunized with diverse HIV vaccines.Nature communications · 2022Article
- Comparative immunogenicity of an mRNA/LNP and a DNA vaccine targeting HIVFrontiers in immunology · 2022Article
- Control of SARS-CoV-2 infection after Spike DNA or Spike DNA+Protein co-immunization in rhesus macaques.PLoS pathogens · 2021Article
- Virus Control in Vaccinated Rhesus Macaques Is Associated with Neutralizing and Capturing Antibodies against the SHIV Challenge Virus but Not with V1V2 Vaccine-Induced Anti-V2 Antibodies Alone.Journal of immunology (Baltimore, Md. : 1950) · 2021Article
- Structure and Fc-Effector Function of Rhesusized Variants of Human Anti-HIV-1 IgG1s.Frontiers in immunology · 2021Article
- Priming with DNA Expressing Trimeric HIV V1V2 Alters the Immune Hierarchy Favoring the Development of V2-Specific Antibodies in Rhesus Macaques.Journal of virology · 2020Article
- Search for antiviral functions of potentially protective antibodies against V2 region of HIV-1.Human vaccines & immunotherapeutics · 2020Article
- Co-immunization of DNA and Protein in the Same Anatomical Sites Induces Superior Protective Immune Responses against SHIV Challenge.Cell reports · 2020Article
- Impact of TJournal of virology · 2020Article
- HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functions.JCI insight · 2020Article
- Rapid Induction of Multifunctional Antibodies in Rabbits and Macaques by Clade C HIV-1 CAP257 Envelopes Circulating During Epitope-Specific Neutralization Breadth Development.Frontiers in immunology · 2020Article
- Article
- ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type.PLoS pathogens · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 9 institutions in 1 country.
Shakti SinghHuman Retrovirus Pathogenesis Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, Maryland, USA.ORCID https://orcid.org/0000-0001-6521-0998
Eric G Ramírez-SalazarHuman Retrovirus Pathogenesis Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, Maryland, USA.ORCID https://orcid.org/0000-0002-0767-9357
Rami DoueiriHuman Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, Maryland, USA.ORCID https://orcid.org/0000-0003-1516-4203
Antonio ValentinHuman Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, Maryland, USA.
Margherita RosatiHuman Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, Maryland, USA.ORCID https://orcid.org/0000-0003-3173-9716
Xintao HuHuman Retrovirus Pathogenesis Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, Maryland, USA.ORCID https://orcid.org/0000-0002-6552-9357
Brandon F KeeleAIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.ORCID https://orcid.org/0000-0002-2381-1151
Xiaoying ShenDuke Human Vaccine Institute, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.ORCID https://orcid.org/0000-0002-8387-3952
Georgia D TomarasDuke Human Vaccine Institute, Department of Immunology, Duke University Medical Center, Durham, North Carolina, USA.ORCID https://orcid.org/0000-0001-8076-1931
Guido FerrariDuke Human Vaccine Institute, Department of Molecular Genetics, Duke University Medical Center, Durham, North Carolina, USA.ORCID https://orcid.org/0000-0001-7747-3349
Celia LaBrancheDuke Human Vaccine Institute, Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA.ORCID https://orcid.org/0000-0002-6653-6655
David C MontefioriDuke Human Vaccine Institute, Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA.ORCID https://orcid.org/0000-0003-0856-6319
Jishnu DasRagon Institute of MGH, MIT, and Harvard University, Cambridge, Massachusetts, USA.ORCID https://orcid.org/0000-0002-5747-064X
Galit AlterRagon Institute of MGH, MIT, and Harvard University, Cambridge, Massachusetts, USA.ORCID https://orcid.org/0000-0003-1570-9445
Hung V TrinhU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.ORCID https://orcid.org/0000-0001-8014-9291
Christopher HamlinU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.ORCID https://orcid.org/0000-0003-0290-6423
Mangala RaoU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.ORCID https://orcid.org/0000-0002-5678-1219
Frances DaytonHuman Retrovirus Pathogenesis Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, Maryland, USA.ORCID https://orcid.org/0000-0002-4473-1951
Jenifer BearHuman Retrovirus Pathogenesis Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, Maryland, USA.ORCID https://orcid.org/0000-0001-5065-6081
Bhabadeb ChowdhuryHuman Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, Maryland, USA.ORCID https://orcid.org/0000-0001-6308-7893
Candido AliceaHuman Retrovirus Pathogenesis Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, Maryland, USA.ORCID https://orcid.org/0000-0003-4434-6858
Jeffrey D LifsonAIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.ORCID https://orcid.org/0000-0002-9494-0268
Kate E BroderickInovio Pharmaceuticals, Inc., Plymouth Meeting, Pennsylvania, USA.ORCID https://orcid.org/0000-0003-2682-2363
Niranjan Y SardesaiInovio Pharmaceuticals, Inc., Plymouth Meeting, Pennsylvania, USA.ORCID https://orcid.org/0000-0001-6920-1167
Sandra J SivananthanInfectious Disease Research Institute, Seattle, Washington, USA.
Christopher B FoxInfectious Disease Research Institute, Seattle, Washington, USA.ORCID https://orcid.org/0000-0002-4644-2619
Steven G ReedInfectious Disease Research Institute, Seattle, Washington, USA.
David J VenzonBiostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA.ORCID https://orcid.org/0000-0002-8990-158X
Vanessa M HirschLaboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0002-1228-7761
George N PavlakisHuman Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, Maryland, USA George.pavlakis@nih.gov Barbara.felber@nih.gov.ORCID https://orcid.org/0000-0002-4027-4036
Barbara K FelberHuman Retrovirus Pathogenesis Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, Maryland, USA George.pavlakis@nih.gov Barbara.felber@nih.gov.ORCID https://orcid.org/0000-0001-8925-8128
Frederick National Laboratory for Cancer Research · USDuke Medical Center · USInfectious Disease Research Institute · USHenry M. Jackson Foundation · USInovio Pharmaceuticals (United States) · USLeidos (United States) · USNational Institutes of Health · USRagon Institute of MGH, MIT and Harvard · USWalter Reed Army Institute of Research · US
Funding
Social and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI GEORGIA Doris TOMARAS · 2005 to 2026
$50.5MImmunotherapeutic Approaches for AIDSZIABC010749 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI PAVLAKIS, GEORGE N. · 2009 to 2022
$21.6MPathogenesis Studies Of Simian Immunodeficiency Virus Infection Of MonkeysZIAAI000370 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI HIRSCH, VANESSA M. · 2009 to 2022
$16.2MVaccine Studies Of Simian Immunodeficiency Virus (SIV) in MacaquesZIAAI000686 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI HIRSCH, VANESSA M. · 2009 to 2018
$10.0MNCI NIH HHS HHSN261200800001ENIAID NIH HHS P30 AI064518
Abstract
We developed a method of simultaneous vaccination with DNA and protein resulting in robust and durable cellular and humoral immune responses with efficient dissemination to mucosal sites and protection against simian immunodeficiency virus (SIV) infection. To further optimize the DNA-protein coimmunization regimen, we tested a SIV
Indexed as
Gene Products, envImmunity, HumoralSAIDS VaccinesSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusVaccines, DNAAdjuvants, ImmunologicAmino Acid SubstitutionAnimalsAntibodies, NeutralizingAntibodies, ViralImmunizationMacacaMutation, MissenseToll-Like Receptor 4Adjuvants, ImmunologicAntibodies, NeutralizingAntibodies, ViralGene Products, envSAIDS VaccinesToll-Like Receptor 4Vaccines, DNAAb glycosylation structuresacquisition delayADCCADCDadjuvantADNPA/K variantbinding antibodycorrelate of viremia controlcyclic V2DNAHIVhumoral responsesimmunizationlinear peptidemucosal responsesneutralizing antibodyproteinQS21reduced risk of infectionrepeated low-dose rectal challengerhesus macaquescaffolded gp70-V1V2SIVmac251SIVsmE660SIVsmE660 T/Fsystems serologyT cell responsesTLR4TLR7TRIM-5αV2 responsesvaccinationvaccineviremia control
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.